Nicole A. Schreiber - Concepedia

Author

Nicole A. Schreiber

Cornell University

Also Known As

Christoph Pitschke, N. Schreiber, N.A. Schreiber, Nicole A Schreiber, Nicole A. Schreiber, Nicole Schreiber

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

Cornell University Memorial Sloan Kettering Cancer Center Epic Sciences (United States)Prostate Cancer Research University of North Carolina at Chapel Hill

About

Nicole A. Schreiber is an author at Cornell University specializing in urology, tumor microenvironment, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	78
2	Pathology	1	1	78
3	Tumor Biology	1	1	78
4	Biomarker Discovery	1	1	78
5	Molecular Diagnostics	1	1	78

Nicole A. Schreiber

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer Howard I. Scher, David Lu, Nicole A. Schreiber, JAMA Oncology	2016	627
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer Karen A. Autio, Robert Dreicer, Justine Anderson, JAMA Oncology	2018	241
Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer Howard I. Scher, Ryon P. Graf, Nicole A. Schreiber, JAMA Oncology	2018	237
Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer Howard I. Scher, Ryon P. Graf, Nicole A. Schreiber, European Urology	2016	181
Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Detected at Four U.S. Wastewater Treatment Plants Rachel E. Rosenberg Goldstein, Shirley A. Micallef, Shawn G. Gibbs, Environmental Health Perspectives	2012	143
The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer Himisha Beltran, Adam Jendrisak, Mark Landers, Clinical Cancer Research	2015	134
Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer Howard I. Scher, Ryon P. Graf, Nicole A. Schreiber, Cancer Research	2017	134
Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer Patients Daniel C. Danila, Aliaksandra Samoila, Chintan Patel, The Cancer Journal Circulating Tumor CellsPathologyTumor BiologyBiomarker (Medicine)Cancer Detection	2016	78
Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy Karen A. Autio, Emmanuel S. Antonarakis, Tina Mayer, European Urology Open Science	2021	17
Development of an immunofluorescent AR-V7 circulating tumor cell assay – A blood-based test for men with metastatic prostate cancer David Lu, Rachel Krupa, Melissa Harvey, Journal of Circulating Biomarkers	2020	16

Page 1